PILA PHARMA

It's a #ViciousCircle! ❌ Did you ever understand the #Mechanism that PILA PHARMA works with? Watch this small clip to understand why we propose that a #TRPV1 antagonist like our lead candidate XEN-D0501 could play a role in #obesity, #diabetes and possibly more conditions! 🌀💡 #PILA #Biotech #Investment #Cardiovascular #Diabetes #Obesity

Big thanks to the Swedish Broadcast Corporation (SVT) for visiting our office in #Malmö and featuring us and our vision of developing a novel treatment of #obesity, #diabetes and more! 💊💡 Obesity and Diabetes remain huge issues in modern societies, including in Sweden, being the driver for many other diseases and increasing the major cost to our #healthcare systems. New and #accessible medicine is key! 🌍 In PILA PHARMA we continue rigorously to push for advancements of the understanding of #TRPV1 and its potential use in #cardiometabolic diseases. Getting national media #exposure is a key part of increasing #awareness! 🫀 Find the link to the interview here: https://lnkd.in/du6AyXdB #PILA #Biotech #Cardiovascular #Diabetes #Obesity #Pain

"The #obesity market has emerged at an insane pace, so we also have to monitor and adjust how we can potentially fit into this space" 💊 We elaborated a little bit about our vision in #Millionærklubben The episode was recorded in end 2024. You can find link to the whole episode (in Danish 🇩🇰) in the comments! #PILA #Biotech #Cardiovascular #Diabetes #Obesity #Pain

"💡 It's not just #Monotherapy in #obesity anymore. We're trying to see how we can position ourselves as a potential alternative" We had a great time elaborating a bit on how we see the market and the increased interest in new #modalities & #combinations, when we visited #Millionærklubben 💊 The episode was recorded in end 2024. You can find link to the whole episode (in Danish 🇩🇰) in the comments! #PILA #Biotech #Cardiovascular #Diabetes #Obesity #Pain

"The #dealmaking comes in waves. The different segments also appears to become quite crowded now so one has to ask if its feasible" Great discussions about the #obesity market, some of the players involved, #acquisitions, #GLP1 & #Amylin were among the topics when the discussion turned on the day when we visited #Millionærklubben ⚡ The episode was recorded in end 2024. You can find link to the whole episode (in Danish 🇩🇰) in the comments! #PILA #Biotech #Cardiovascular #Diabetes #Obesity #Pain

"The #obesity trend is not something that will end in the foreseeable future" 🌎 Discussions #obesity market, #diabetes costs and #biotech as investment class were among the topics on the day when we visited #Millionærklubben ⚡ The episode was recorded in end 2024. You can find link to the whole episode (in Danish 🇩🇰) in the comments! #PILA #Biotech #Cardiovascular #Diabetes #Obesity #Pain

Did you miss our participation at Danish podcast #Millionærklubben? Discussions on #obesity market, #diabetes costs and #biotech as investment class were among the topics on the day ⚡ The episode was recorded in end 2024. You can find link to the whole episode (in Danish 🇩🇰) in the comments! #PILA #Biotech #Cardiovascular #Diabetes #Obesity #Pain

Investors worldwide are scouring for their next big win after the door to the extremely lucrative obesity market was opened by pharmaceutical giants Novo Nordisk and Eli Lilly and Company. Now benefiting on the Swedish stock exchange is a smaller biotech company - PILA PHARMA. https://lnkd.in/eaavMJFn #pharma #drugdevelopment #obesity

Thanks to world renowned #medical media outlet Medscape for the feature highlighting our lead asset, a #TRPV1-antagonist XEN-D0501! Link to article: https://lnkd.in/dc8ZW96M Link to PDF: https://lnkd.in/dfMrQp2F #PILA #Biotech #Cardiovascular #Diabetes #Obesity #Pain

#PRESS: PILA PHARMA ANNOUNCES PRECLINICAL PROOF-OF-CONCEPT ACHIEVED IN CARDIOVASCULAR DISEASE STUDY https://lnkd.in/dbbtESsV #PILA #Biotech #Cardiovascular #Diabetes #Obesity #Pain